Immatics N.V.(IMTX)Earnings, Financials & Key Ratios
IMTX•NASDAQ
Price updated Jun 19, 2026
AboutImmatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Show more
- Revenue$48M-69.0%
- EBITDA-$170M-542.7%
- Net Income-$196M-1390.9%
- EPS (Diluted)-1.54-1200.0%
- Gross Margin100%
- EBITDA Margin-351.42%-1975.2%
- Operating Margin-377.11%-1421.9%
- Net Margin-407.01%-4267.8%
- ROE-37.11%-1075.3%
IMTX Key Insights
Immatics N.V. (IMTX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
✗Weaknesses
- ✗Weak Piotroski F-Score: 2/9
- ✗Negative free cash flow
- ✗Shares diluted 14.6% in last year
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when IMTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
IMTX Price & Volume
Immatics N.V. (IMTX) stock price & volume — 10-year historical chart
Loading chart...
IMTX Growth Metrics
Immatics N.V. (IMTX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years9.08%
3 Years-34.64%
TTM-74.13%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-897.76%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-1040%
Return on Capital
10 Years-42.26%
5 Years-23.61%
3 Years-23.56%
Last Year-31.73%
IMTX Recent Earnings
Immatics N.V. (IMTX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 8/12 qtrs (67%)●Beat Revenue 8/12 qtrs (67%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.50-19.0%
$0.42
Rev
$9M-10.3%
$10M
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.34+29.2%
$0.48
Rev
$22M+98.2%
$11M
Q4 2025
Nov 17, 2025Metric
Actual
Est
EPS
$0.49-11.5%
$0.44
Rev
$6M-43.3%
$11M
Q3 2025
Aug 13, 2025Metric
Actual
Est
EPS
$0.66-73.7%
$0.38
Rev
$6M-55.5%
$13M
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.50vs $0.42-19.0% | $9Mvs $10M-10.3% |
| Q2 2026 | Mar 5, 2026 | $0.34vs $0.48+29.2% | $22Mvs $11M+98.2% |
| Q4 2025 | Nov 17, 2025 | $0.49vs $0.44-11.5% | $6Mvs $11M-43.3% |
| Q3 2025 | Aug 13, 2025 | $0.66vs $0.38-73.7% | $6Mvs $13M-55.5% |
Based on last 12 quarters of dataView full earnings history →
IMTX Peer Comparison
Immatics N.V. (IMTX) competitors in Cell and Gene Therapy Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 TCRT | 5.25M | 2.15 | -0.98 | -50% | -1369.67% | -165.94% | ||
 AGEN | 124.93M | 3.00 | -882.35 | 10.37% | 52.16% | |||
 FATE | 243.61M | 2.09 | -1.82 | -51.24% | -20.57% | -58.89% | 0.38 | |
 CRIS | 81.52M | 0.42 | -0.73 | -13.43% | -299.66% | -138.81% | 0.30 | |
 NKTX | 204.62M | 2.86 | -2.03 | -30.9% | 0.24 | |||
 KYMR | 7.38B | 90.43 | -24.51 | -16.72% | -6.12% | -25.02% | 0.05 | |
 RCUS | 2.45B | 24.31 | -7.39 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 7.26B | 35.34 | -12.76 | -68.16% | 0.00 |
Compare IMTX vs Peers
Immatics N.V. (IMTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
IMTX Income Statement
Immatics N.V. (IMTX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 3.77M | 18.45M | 31.25M | 34.76M | 172.83M | 54M | 155.84M | 48.27M | 37.3M |
Revenue Growth % | - | 389.36% | 69.4% | 11.23% | 397.17% | -68.76% | 188.6% | -69.03% | -74.13% |
Cost of Goods Sold | 33.97M | 40.09M | 67.08M | 87.57M | 106.78M | 118.66M | 0 | 0 | 0 |
COGS % of Revenue | 901.09% | 217.31% | 214.65% | 251.92% | 61.78% | 219.76% | - | - | - |
Gross Profit | -30.2M▲ 0% | -21.64M▲ 28.3% | -35.83M▼ 65.6% | -52.81M▼ 47.4% | 66.05M▲ 225.1% | -64.67M▼ 197.9% | 155.84M▲ 341.0% | 48.27M▼ 69.0% | 37.3M▲ 0% |
Gross Margin % | -801.09% | -117.31% | -114.65% | -151.92% | 38.22% | -119.76% | 100% | 100% | 100% |
Gross Profit Growth % | - | 28.34% | -65.57% | -47.38% | 225.07% | -197.9% | 340.98% | -69.03% | - |
Operating Expenses | 38.18M | 51.46M | 100.97M | 121.05M | 142.88M | 155.72M | 194.45M | 230.28M | 250M |
OpEx % of Revenue | 1012.71% | 278.94% | 323.07% | 348.22% | 82.67% | 288.39% | 124.78% | 477.11% | - |
Selling, General & Admin | 7.67M | 11.76M | 34.19M | 33.81M | 36.12M | 38.2M | 46.45M | 51.18M | 51.05M |
SG&A % of Revenue | 203.34% | 63.72% | 109.38% | 97.25% | 20.9% | 70.74% | 29.81% | 106.05% | - |
Research & Development | 33.97M | 40.09M | 67.08M | 87.57M | 106.78M | 118.66M | 148.08M | 183.83M | 202.08M |
R&D % of Revenue | 901.09% | 217.31% | 214.65% | 251.92% | 61.78% | 219.76% | 95.02% | 380.87% | - |
Other Operating Expenses | -3.46M | -385K | -303K | -332K | -26K | -1.14M | -78K | -4.73M | -51K |
Operating Income | -34.41M▲ 0% | -33.01M▲ 4.1% | -69.72M▼ 111.2% | -86.29M▼ 23.8% | 29.95M▲ 134.7% | -101.72M▼ 439.6% | -38.62M▲ 62.0% | -182.02M▼ 371.4% | -213.82M▲ 0% |
Operating Margin % | -912.71% | -178.94% | -223.07% | -248.24% | 17.33% | -188.39% | -24.78% | -377.11% | -573.28% |
Operating Income Growth % | - | 4.06% | -111.17% | -23.78% | 134.71% | -439.6% | 62.04% | -371.36% | - |
EBITDA | -32.16M | -29.17M | -65.59M | -80.82M | 36.8M | -94.49M | -26.39M | -169.62M | -201.74M |
EBITDA Margin % | -853.14% | -158.09% | -209.88% | -232.5% | 21.29% | -174.99% | -16.93% | -351.42% | -540.89% |
EBITDA Growth % | - | 9.32% | -124.89% | -23.22% | 145.53% | -356.8% | 72.07% | -542.73% | -318.8% |
D&A (Non-Cash Add-back) | 2.25M | 3.85M | 4.12M | 5.47M | 6.84M | 7.23M | 12.22M | 12.4M | 12.08M |
EBIT | -32.34M | -32.32M | -211.55M | -92.77M | 43.07M | -96.16M | 22.23M | -197.49M | -224.06M |
Net Interest Income | 491K | 620K | 561K | -433K | 1.44M | 13.01M | 24.11M | 16.23M | 14.41M |
Interest Income | 507K | 790K | 850K | 133K | 2.48M | 13.85M | 25M | 17.18M | 15.35M |
Interest Expense | 16K | 170K | 289K | 566K | 1.04M | 831K | 886K | 946K | 942.98K |
Other Income/Expense | 2.05M | 526K | -142.13M | -7.04M | 12.08M | 4.73M | 59.96M | -16.42M | -2.48M |
Pretax Income | -32.35M▲ 0% | -32.49M▼ 0.4% | -229.62M▼ 606.8% | -93.33M▲ 59.4% | 42.04M▲ 145.0% | -96.99M▼ 330.7% | 21.35M▲ 122.0% | -198.44M▼ 1029.6% | -216.3M▲ 0% |
Pretax Margin % | -858.22% | -176.09% | -734.7% | -268.49% | 24.32% | -179.63% | 13.7% | -411.13% | -579.93% |
Income Tax | 0 | 0 | -268K | 0 | 4.55M | 0 | 6.13M | -1.99M | -941.15K |
Effective Tax Rate % | 0% | 0% | 0.12% | 0% | 10.83% | 0% | 28.71% | 1% | 0.44% |
Net Income | -31.44M▲ 0% | -31.74M▼ 0.9% | -229.35M▼ 622.6% | -95.06M▲ 58.6% | 37.51M▲ 139.5% | -96.99M▼ 358.6% | 15.22M▲ 115.7% | -196.45M▼ 1390.9% | -215.36M▲ 0% |
Net Margin % | -834.06% | -172.05% | -733.84% | -273.45% | 21.71% | -179.63% | 9.77% | -407.01% | -577.41% |
Net Income Growth % | - | -0.94% | -622.56% | 58.55% | 139.46% | -358.55% | 115.69% | -1390.89% | -897.76% |
Net Income (Continuing) | -32.35M | -32.49M | -211.84M | -93.33M | 37.51M | -96.99M | 15.22M | -196.45M | -215.36M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 1.24M | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -0.50▲ 0% | -0.50▲ 0.0% | -4.78▼ 856.0% | -1.51▲ 68.4% | 0.54▲ 135.8% | -1.20▼ 322.2% | 0.14▲ 111.7% | -1.54▼ 1200.0% | -1.60▲ 0% |
EPS Growth % | - | 0% | -856% | 68.41% | 135.76% | -322.22% | 111.67% | -1200% | -1040% |
EPS (Basic) | -0.50 | -0.50 | -4.78 | -1.51 | 0.55 | -1.20 | 0.14 | -1.54 | - |
Diluted Shares Outstanding | 62.91M | 62.91M | 48M | 62.91M | 68.82M | 80.55M | 106.8M | 122.35M | 134.64M |
Basic Shares Outstanding | 62.91M | 62.91M | 48M | 62.91M | 67.22M | 80.55M | 108.7M | 122.35M | 134.64M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
IMTX Balance Sheet
Immatics N.V. (IMTX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 55.29M | 124M | 238.99M | 152.21M | 377.15M | 449.37M | 629.55M | 503.79M | 485.34M |
Cash & Short-Term Investments | 52.47M | 119.38M | 231.98M | 145.12M | 362.2M | 425.89M | 604.45M | 469.14M | 454.04M |
Cash Only | 39.37M | 103.35M | 207.53M | 132.99M | 148.52M | 218.47M | 236.75M | 345.77M | 301.65M |
Short-Term Investments | 13.1M | 16.02M | 24.45M | 12.12M | 213.69M | 207.42M | 367.7M | 123.37M | 152.4M |
Accounts Receivable | 1.82M | 2.72M | 2.92M | 2.36M | 1.11M | 5.74M | 6.75M | 6.88M | 4.82M |
Days Sales Outstanding | 176.01 | 53.87 | 34.14 | 24.77 | 2.35 | 38.78 | 15.8 | 52.01 | 48.12 |
Inventory | 0 | 1.24M | 3.3M | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | 11.25 | 17.97 | - | - | - | - | - | - |
Other Current Assets | 1M | 665K | 1.7M | 950K | 13.84M | 7.12M | 6.31M | 14.86M | 17.61M |
Total Non-Current Assets | 6.03M | 10.28M | 15.65M | 22.44M | 30.67M | 60.59M | 66.59M | 58.3M | 58.49M |
Property, Plant & Equipment | 4.01M | 8.01M | 14.02M | 20.49M | 26.49M | 57.05M | 63.71M | 54.87M | 53.49M |
Fixed Asset Turnover | 0.94x | 2.30x | 2.23x | 1.70x | 6.52x | 0.95x | 2.45x | 0.88x | 0.63x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 1.04M | 1.01M | 913K | 1.31M | 1.63M | 1.52M | 1.63M | 1.58M | 1.58M |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 984K | 1.26M | 726K | 636K | 2.54M | 2.02M | 1.25M | 1.85M | 3.41M |
Total Assets | 61.32M▲ 0% | 134.28M▲ 119.0% | 254.65M▲ 89.6% | 174.65M▼ 31.4% | 407.82M▲ 133.5% | 509.96M▲ 25.0% | 696.15M▲ 36.5% | 562.1M▼ 19.3% | 543.83M▲ 0% |
Asset Turnover | 0.06x | 0.14x | 0.12x | 0.20x | 0.42x | 0.11x | 0.22x | 0.09x | 0.07x |
Asset Growth % | - | 118.98% | 89.64% | -31.42% | 133.51% | 25.05% | 36.51% | -19.26% | -38.47% |
Total Current Liabilities | 26.84M | 69.3M | 60.61M | 95.15M | 106.45M | 156.55M | 67.99M | 42.99M | 55.31M |
Accounts Payable | 4.8M | 4.87M | 2.55M | 3.01M | 4.03M | 7.67M | 10.11M | 339.86K | 8.06M |
Days Payables Outstanding | 51.6 | 44.3 | 13.9 | 12.54 | 13.76 | 23.58 | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.76M | 2.61M |
Deferred Revenue (Current) | 21.75M | 59.63M | 46.6M | 50.4M | 64.96M | 100.4M | 35.91M | 15.81M | 83.47M |
Other Current Liabilities | 888K | 65K | 212K | 28.04M | 17.88M | 20.48M | 4.77M | 22.35M | 29.35M |
Current Ratio | 2.06x | 1.79x | 3.94x | 1.60x | 3.54x | 2.87x | 9.26x | 11.72x | 8.78x |
Quick Ratio | 2.06x | 1.77x | 3.89x | 1.60x | 3.54x | 2.87x | 9.26x | 11.72x | 8.78x |
Cash Conversion Cycle | - | 20.82 | 38.21 | - | - | - | - | - | 48.12 |
Total Non-Current Liabilities | 43.65M | 105.82M | 89.78M | 55.44M | 88.2M | 128.33M | 53.32M | 35.21M | 32.25M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Capital Lease Obligations | 0 | 1.82M | 4.31M | 7.14M | 12.4M | 12.8M | 13.35M | 12.87M | 55.33M |
Deferred Tax Liabilities | 0 | 0 | -4.31M | 0 | 0 | 0 | 5.8M | 3.81M | 15.8M |
Other Non-Current Liabilities | 220K | 2.08M | 4.31M | 68K | 42K | 115.53M | 0 | 0 | 0 |
Total Liabilities | 70.49M | 175.11M | 150.39M | 150.58M | 194.66M | 284.88M | 121.3M | 78.2M | 87.55M |
Total Debt | 0 | 3.23M | 6.19M | 9.85M | 14.56M | 15.4M | 16.2M | 15.63M | 15.1M |
Net Debt | -39.37M | -100.12M | -201.34M | -123.14M | -133.96M | -203.07M | -220.54M | -330.14M | -286.55M |
Debt / Equity | - | - | 0.06x | 0.41x | 0.07x | 0.07x | 0.03x | 0.03x | 0.03x |
Debt / EBITDA | - | - | - | - | 0.40x | - | - | - | -0.07x |
Net Debt / EBITDA | - | - | - | - | -3.64x | - | - | - | 1.42x |
Interest Coverage | -2021.19x | -190.10x | -732.01x | -163.90x | 41.50x | -115.72x | 25.09x | -208.76x | -237.61x |
Total Equity | -9.17M▲ 0% | -40.84M▼ 345.3% | 104.26M▲ 355.3% | 24.06M▼ 76.9% | 213.16M▲ 785.9% | 225.08M▲ 5.6% | 574.84M▲ 155.4% | 483.89M▼ 15.8% | 456.28M▲ 0% |
Equity Growth % | - | -345.26% | 355.31% | -76.92% | 785.86% | 5.59% | 155.39% | -15.82% | 16.97% |
Book Value per Share | -0.15 | -0.65 | 2.17 | 0.38 | 3.10 | 2.79 | 5.38 | 3.96 | 3.39 |
Total Shareholders' Equity | -10.41M | -41.85M | 104.26M | 24.06M | 213.16M | 225.08M | 574.84M | 483.89M | 456.28M |
Common Stock | 1.16M | 1.16M | 629K | 629K | 767K | 847K | 1.22M | 1.34M | 1.37M |
Retained Earnings | -201.62M | -233.19M | -462.25M | -537.81M | -500.3M | -597.29M | -589.54M | -785.65M | -844.68M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | -741K | -770K | -7.46M | -3.94M | -1.48M | -1.64M | 1.03M | -8.59M | -6.72M |
Minority Interest | 1.24M | 1.02M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMTX Cash Flow Statement
Immatics N.V. (IMTX) cash flow — operating, investing & free cash flow history
| Metric | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 20.68M | 70.97M | -85.61M | -81.78M | 100.13M | 18.23M | -158.03M | -169.66M | -184.13M |
Operating CF Margin % | 548.65% | 384.67% | -273.93% | -235.26% | 57.94% | 33.76% | -101.41% | -351.5% | - |
Operating CF Growth % | - | 243.1% | -220.63% | 4.47% | 222.43% | -81.8% | -966.96% | -7.36% | -73.6% |
Net Income | -32.35M | -32.49M | -229.62M | -93.33M | 37.51M | -94.65M | 15.22M | -188.69M | -215.36M |
Depreciation & Amortization | 2.18M | 3.86M | 4.42M | 5.26M | 6.97M | 7.23M | 12.22M | 11.91M | 12.05M |
Stock-Based Compensation | 1.48M | 852K | 22.95M | 26.4M | 22.57M | 20.7M | 17.64M | 0 | 7.38M |
Deferred Taxes | 491K | 623K | -3.96M | 11.15M | 4.52M | 0 | 6.13M | 0 | 1.17M |
Other Non-Cash Items | -271K | 1.24M | 145.87M | 433K | -8.7M | 3.31M | -45.37M | 49.36M | 26.46M |
Working Capital Changes | 49.16M | 96.88M | -25.28M | -31.7M | 37.26M | 81.63M | -163.88M | -42.23M | -14.05M |
Change in Receivables | -175K | -563K | -294K | 569K | -429K | -2.98M | -1.76M | -232.45K | 1.5M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | -84.24M | 0 | 0 | 0 |
Change in Payables | 43.73M | 98.94M | -23.39M | -31.78M | 45.56M | 84.24M | 0 | -36.13M | -11.74M |
Cash from Investing | -13.51M | -5.06M | -15.95M | 7.49M | -209.79M | -31.39M | -152.39M | 196.7M | 128.77M |
Capital Expenditures | -507K | -2.23M | -7.52M | -5.66M | -6.21M | -30.8M | -16.27M | -6.54M | -4.28M |
CapEx % of Revenue | 13.45% | 12.11% | 24.07% | 16.27% | 3.6% | 57.04% | 10.44% | 13.54% | 11.48% |
Acquisitions | 97.01K | 91K | 104K | 551K | -199.91M | 0 | 0 | 0 | -22.35K |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | 94K | 6K | -104K | -551K | 199.96M | -8K | -206K | 0 | -130K |
Cash from Financing | 23.65M | -1.86M | 207.88M | -2.61M | 123.71M | 84.52M | 319.68M | 93.51M | 118.48M |
Debt Issued (Net) | 0 | -1.86M | -2.1M | -2.71M | -2.84M | -3.85M | -2.01M | 0 | -1.47M |
Equity Issued (Net) | 23.65M | 0 | 217.92M | 94K | 134.48M | 90.4M | 343.01M | 96.35M | 121.46M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Financing | 0 | 0 | -7.94M | 0 | -7.93M | -2.04M | -21.31M | -2.84M | -1.5M |
Net Change in Cash | 30.95M▲ 0% | 63.99M▲ 106.7% | 104.18M▲ 62.8% | -74.54M▼ 171.5% | 15.53M▲ 120.8% | 69.95M▲ 350.6% | 18.28M▼ 73.9% | 137.12M▲ 650.3% | 51.59M▲ 0% |
Free Cash Flow | 20.18M▲ 0% | 68.73M▲ 240.7% | -93.13M▼ 235.5% | -87.44M▲ 6.1% | 93.92M▲ 207.4% | -12.73M▼ 113.6% | -174.51M▼ 1271.0% | -175.95M▼ 0.8% | -188.49M▲ 0% |
FCF Margin % | 535.2% | 372.56% | -298% | -251.53% | 54.34% | -23.57% | -111.98% | -364.55% | -505.38% |
FCF Growth % | - | 240.65% | -235.5% | 6.11% | 207.41% | -113.55% | -1270.96% | -0.83% | -10.83% |
FCF per Share | 0.32 | 1.09 | -1.94 | -1.39 | 1.36 | -0.16 | -1.63 | -1.44 | -1.40 |
FCF Conversion (FCF/Net Income) | -0.66x | -2.24x | 0.37x | 0.86x | 2.67x | -0.19x | -10.38x | 0.86x | 0.88x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
IMTX Key Ratios
Immatics N.V. (IMTX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | - | -723.26% | -148.16% | 31.63% | -44.26% | 3.8% | -37.11% | -45.47% |
Return on Invested Capital (ROIC) | - | - | - | 28.36% | -150.75% | -15.39% | -53.74% | -96.63% |
Gross Margin | -117.31% | -114.65% | -151.92% | 38.22% | -119.76% | 100% | 100% | 100% |
Net Margin | -172.05% | -733.84% | -273.45% | 21.71% | -179.63% | 9.77% | -407.01% | -577.41% |
Debt / Equity | - | 0.06x | 0.41x | 0.07x | 0.07x | 0.03x | 0.03x | 0.03x |
Interest Coverage | -190.10x | -732.01x | -163.90x | 41.50x | -115.72x | 25.09x | -208.76x | -237.61x |
FCF Conversion | -2.24x | 0.37x | 0.86x | 2.67x | -0.19x | -10.38x | 0.86x | 0.88x |
Revenue Growth | 389.36% | 69.4% | 11.23% | 397.17% | -68.76% | 188.6% | -69.03% | -74.13% |
Related:IMTX Dividend History·IMTX Revenue History·IMTX Price History·IMTX P/E History·IMTX Financial Ratios·IMTX Institutional Holders
IMTX Frequently Asked Questions
Immatics N.V. (IMTX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Immatics N.V. (IMTX) reported $37.3M in revenue for fiscal year 2025. This represents a 889% increase from $3.8M in 2018.
Immatics N.V. (IMTX) saw revenue decline by 69.0% over the past year.
Immatics N.V. (IMTX) reported a net loss of $215.4M for fiscal year 2025.
Dividend & Returns
Immatics N.V. (IMTX) has a return on equity (ROE) of -37.1%. Negative ROE indicates the company is unprofitable.
Immatics N.V. (IMTX) had negative free cash flow of $188.5M in fiscal year 2025, likely due to heavy capital investments.